Skip to main content
. 2014 Feb 20;9(2):e87711. doi: 10.1371/journal.pone.0087711

Table 6. Main Therapeutic Options on Influenza for Children According to Guidelines.

Therapy recommended H1N1 H3N2 H5N1 Influenza-like syndrome
Harper 2009, IDSA Bautista 2009, WHO Harper 2009, IDSA Bellamy 2006, WHO Harper 2009, IDSA Morciano 2009, SNLG
Target of population Children>1 year Children (≤12) and Adolescents(13–18 years) Children >1 year Children Children >1 year Children
Antivirals
Onset of antivirals Laboratory-confirmed or highly suspected infection (A, II) Confirmed or strongly suspected infection (Low, Strong) Laboratory-confirmed or highly suspected infection (A, II) Confirmed or strongly suspected infection Laboratory-confirmed or highly suspected infection (A, II) Post-exposure prophylaxis in non-vaccinated institutionalized patients
Choose of antivirals Zanamivir, adamantine (rimantadine) (A, II) Pandemic H1N1 with severe or progressive clinical illness: oseltamivir (Low, strong) Uncomplicated pandemic H1N1: oseltamivir, zanamivir(Low,strong) Oseltamivir, zanamivir (A-II) Oseltamivir (strong, very low), zanamivir (≥7 years) (weak, very low). Oseltamivir, zanamivir (A-II) Oseltamivir (C/I)
Antibiotics
Severe community-acquired pneumonia: follow guidelines (strong) Mechanical ventilation: recommend treatment or prevention of ventilator associated or hospital acquired pneumonia (strong) Non-complicated: NR1(E/I) Influenza-like syndrome-related sore throat: NR, unless symptoms are complicated by bacterial infections(D/I)
NSAIs
Aspirin: NR (strong, regulatory warning) Paracetamol, ibuprofen (B/I)

Notes:

1

NR: not recommended.